Cipher Pharmaceuticals Inc (CPH) - Total Liabilities
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has total liabilities worth CA$20.55 Million CAD (≈ $14.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cipher Pharmaceuticals Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See CPH working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Cipher Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
|
India | Rs8.29 Billion |
|
LIBERTY LAT.AMER.A DL-01
F:1LL
|
Germany | €11.16 Billion |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
China | CN¥479.61 Million |
|
Antipa Minerals Ltd
AU:AZY
|
Australia | AU$2.45 Million |
|
Sarana Meditama Metropolitan
JK:SAME
|
Indonesia | Rp1.58 Trillion |
|
Hutchison Telecommunications (Australia) Ltd
AU:HTA
|
Australia | AU$51.03 Million |
|
Digital Imaging Technology INC
KQ:110990
|
Korea | ₩25.61 Billion |
|
Jiangsu Fengshan Group Co Ltd
SHG:603810
|
China | CN¥1.13 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Cipher Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CPH stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cipher Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual total liabilities of Cipher Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$30.20 Million ≈ $21.85 Million |
-49.80% |
| 2024-12-31 | CA$60.17 Million ≈ $43.53 Million |
+991.80% |
| 2023-12-31 | CA$5.51 Million ≈ $3.99 Million |
-43.16% |
| 2022-12-31 | CA$9.70 Million ≈ $7.01 Million |
-23.98% |
| 2021-12-31 | CA$12.75 Million ≈ $9.23 Million |
+9.63% |
| 2020-12-31 | CA$11.63 Million ≈ $8.42 Million |
-36.92% |
| 2019-12-31 | CA$18.44 Million ≈ $13.34 Million |
-40.36% |
| 2018-12-31 | CA$30.93 Million ≈ $22.37 Million |
-23.06% |
| 2017-12-31 | CA$40.19 Million ≈ $29.08 Million |
-32.32% |
| 2016-12-31 | CA$59.39 Million ≈ $42.96 Million |
+7.23% |
| 2015-12-31 | CA$55.39 Million ≈ $40.07 Million |
+1126.12% |
| 2014-12-31 | CA$4.52 Million ≈ $3.27 Million |
-71.36% |
| 2013-12-31 | CA$15.77 Million ≈ $11.41 Million |
+64.30% |
| 2012-12-31 | CA$9.60 Million ≈ $6.94 Million |
+89.96% |
| 2011-12-31 | CA$5.05 Million ≈ $3.66 Million |
+7.55% |
| 2010-12-31 | CA$4.70 Million ≈ $3.40 Million |
+27.61% |
| 2009-12-31 | CA$3.68 Million ≈ $2.66 Million |
+33.79% |
| 2008-12-31 | CA$2.75 Million ≈ $1.99 Million |
-10.39% |
| 2007-12-31 | CA$3.07 Million ≈ $2.22 Million |
+242.85% |
| 2006-12-31 | CA$895.68K ≈ $647.92K |
-69.92% |
| 2005-12-31 | CA$2.98 Million ≈ $2.15 Million |
-57.48% |
| 2004-12-31 | CA$7.00 Million ≈ $5.07 Million |
-- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more